{"id":"asenapine-double-blind","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"5-10","effect":"Parkinsonism"},{"rate":"5-10","effect":"Oral hypoesthesia/paresthesia"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asenapine acts as an antagonist at multiple neurotransmitter receptors, primarily D2 dopamine receptors and 5-HT2A serotonin receptors. This dual antagonism helps alleviate positive symptoms of psychosis (hallucinations, delusions) and mood symptoms associated with schizophrenia and bipolar disorder. The sublingual formulation allows for rapid absorption and potentially improved patient compliance.","oneSentence":"Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:45.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"}]},"trialDetails":[{"nctId":"NCT00143182","phase":"PHASE3","title":"9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-07","conditions":"Bipolar Disorder","enrollment":504},{"nctId":"NCT00156104","phase":"PHASE3","title":"Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07-01","conditions":"Schizophrenia","enrollment":460},{"nctId":"NCT00159796","phase":"PHASE3","title":"3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-14","conditions":"Bipolar Disorder","enrollment":489},{"nctId":"NCT00159744","phase":"PHASE3","title":"3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11-30","conditions":"Bipolar Disorder","enrollment":488},{"nctId":"NCT00212836","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04-21","conditions":"Schizophrenia","enrollment":481},{"nctId":"NCT00156117","phase":"PHASE3","title":"Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-12","conditions":"Schizophrenia","enrollment":417},{"nctId":"NCT00212784","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1225},{"nctId":"NCT00151424","phase":"PHASE3","title":"Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-15","conditions":"Schizophrenia","enrollment":277},{"nctId":"NCT01098110","phase":"PHASE3","title":"6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-05-25","conditions":"Schizophrenia","enrollment":532},{"nctId":"NCT01617187","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-04","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00764478","phase":"PHASE3","title":"Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-04-06","conditions":"Bipolar 1 Disorder","enrollment":367},{"nctId":"NCT01190254","phase":"PHASE3","title":"Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-28","conditions":"Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated","enrollment":306},{"nctId":"NCT00145470","phase":"PHASE3","title":"12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-06-02","conditions":"Bipolar Disorder","enrollment":326},{"nctId":"NCT00156091","phase":"PHASE3","title":"Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Schizophrenia","enrollment":260},{"nctId":"NCT00174265","phase":"PHASE3","title":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Schizophrenia","enrollment":196},{"nctId":"NCT00265343","phase":"PHASE3","title":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Schizophrenia","enrollment":306},{"nctId":"NCT00159783","phase":"PHASE3","title":"40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Bipolar Disorder","enrollment":218},{"nctId":"NCT00145496","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12","conditions":"Schizophrenia","enrollment":468},{"nctId":"NCT00150176","phase":"PHASE3","title":"To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Schizophrenia","enrollment":831},{"nctId":"NCT00145509","phase":"PHASE3","title":"40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Bipolar Disorder","enrollment":77},{"nctId":"NCT00156065","phase":"PHASE3","title":"Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Schizophrenia","enrollment":187},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT02876900","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.","status":"COMPLETED","sponsor":"Noven Pharmaceuticals, Inc.","startDate":"2016-08","conditions":"Schizophrenia","enrollment":617},{"nctId":"NCT01400113","phase":"PHASE4","title":"Treating Acutely Agitated Patients With Asenapine Sublingual Tablets","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2012-04","conditions":"Agitation","enrollment":120},{"nctId":"NCT01396291","phase":"PHASE3","title":"Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Bipolar 1 Disorder","enrollment":561},{"nctId":"NCT01395992","phase":"PHASE3","title":"Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-04","conditions":"Bipolar I Disorder","enrollment":165},{"nctId":"NCT01617200","phase":"PHASE3","title":"Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-12","conditions":"Schizophrenia","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Org 5222, SCH 900274, Saphris"],"phase":"phase_3","status":"active","brandName":"Asenapine - Double Blind","genericName":"Asenapine - Double Blind","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Asenapine is a small molecule medication used to treat conditions such as bipolar disorder, bipolar I disorder, schizophrenia, and schizophrenia with disorganized symptoms. The exact mechanism of action of asenapine is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}